Insmed (INSM) Scheduled to Post Earnings on Thursday

Insmed (NASDAQ:INSM) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The company had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $82.15 million. During the same period last year, the company earned ($1.20) earnings per share. The business’s revenue for the quarter was up 41.1% on a year-over-year basis. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Insmed Stock Up 0.5 %

Shares of NASDAQ:INSM opened at $26.08 on Wednesday. The company’s fifty day moving average is $26.65 and its two-hundred day moving average is $27.08. The company has a market cap of $3.87 billion, a P/E ratio of -4.88 and a beta of 0.93. Insmed has a 12-month low of $18.08 and a 12-month high of $32.00.

Analysts Set New Price Targets

INSM has been the topic of several recent analyst reports. Wolfe Research initiated coverage on Insmed in a research report on Thursday, February 15th. They set an “outperform” rating and a $42.00 price target on the stock. Guggenheim increased their price target on shares of Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. StockNews.com downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research report on Monday. Truist Financial assumed coverage on shares of Insmed in a research report on Tuesday, April 23rd. They issued a “buy” rating and a $48.00 target price for the company. Finally, Barclays lifted their target price on shares of Insmed from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and a consensus price target of $44.92.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.